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Abstract
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the
tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-
associated stromal cells, targeting both cell compartments may profoundly influence viral efficacy. Therefore, we developed
SPARC promoter-based CRAds since the SPARC gene is expressed both in malignant cells and in tumor-associated stromal
cells. These CRAds, expressing or not the Herpes Simplex thymidine kinase gene (Ad-F512 and Ad(I)-F512-TK, respectively)
exerted a lytic effect on a panel of human melanoma cells expressing SPARC; but they were completely attenuated in
normal cells of different origins, including fresh melanocytes, regardless of whether cells expressed or not SPARC.
Interestingly, both CRAds displayed cytotoxic activity on SPARC positive-transformed human microendothelial HMEC-1 cells
and WI-38 fetal fibroblasts. Both CRAds were therapeutically effective on SPARC positive-human melanoma tumors growing
in nude mice but exhibited restricted efficacy in the presence of co-administered HMEC-1 or WI-38 cells. Conversely, co-
administration of HMEC-1 cells enhanced the oncolytic efficacy of Ad(I)-F512-TK on SPARC-negative MIA PaCa-2 pancreatic
cancer cells in vivo. Moreover, conditioned media produced by stromal cells pre-infected with the CRAds enhanced the in
vitro viral oncolytic activity on pancreatic cancer cells, but not on melanoma cells. The whole data indicate that stromal cells
might play an important role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.
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Introduction
The concept that the stromal microenvironment is a crucial
regulator of tumor development was originally proposed by Paget
many years ago in his ‘‘seed and soil’’ hypothesis [1]. Essentially,
tumors are heterogeneous organs that in addition to the malignant
cells contain cancer-associated fibroblasts, endothelial and inflam-
matory cells [1,2]. These tumor-companion cells are intermingled
in the tumor-associated stroma that comprises most of the tumor
mass in many carcinomas and provide the soil in which malignant
cells will grow, invade and metastasize [3–5]. Malignant and
stromal cells communicate one to each other through cell-cell and
cell-matrix interactions and secretion of soluble factors, providing
an intratumor connection that is essential for tumors growing
beyond a certain size [5]. Despite this evidence, only recently
research in cancer turn to the tumor environment aiming to
establish how malignant and stromal cells communicate and
‘‘coconspirate’ in tumor development [6].
Conditionally replicative adenoviruses (CRAd) are engineered
to selectively replicate within and kill tumor cells through the use
of ‘‘cancer cell’’-selective promoter elements that transcriptionally
restrict expression of genes essential for CRAd replication [7].
Different CRAds had recently reached the clinic although they did
not realize the expectations regarding their potential therapeutic
effectiveness [8]. Different strategies were applied to improve
CRAds efficacy including viral retargeting through the exchange
of the capsid fiber or addition of specific moieties such as the RGD
that will retarget vectors to enter the cell through cell surface
integrins [9,10].
Despite those efforts, clinical CRAds efficacy is still limited and
the reasons for that remain elusive, although viral spread or
‘‘lateralization’’ appears as one of the most important aspects.
Stromal cells -especially fibroblasts- can impose limitations for
lateral spread because of their physical presence and their capacity
to produce extracellular matrix that might affect CRAd activity
and interaction with malignant cells. In this regard, CRAd limited
efficacy might arise in part from the fact that they are generally
designed to target the malignant cell compartment alone while no
attention was paid on neighbor stromal cells. Only very recently
efforts were aimed to combine CRAd activity with enzymatic
degradation of the stroma [11] with the potential risk of releasing
tumor cells to the circulation. However, no evidence was presented
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Since stromal cells ‘‘cross talk’’ with malignant cells can define
tumor outcome it can be hypothesized that, unless simultaneously
targeted, they will severely limit CRAd replication and spreading.
SPARC (Secreted Protein Acidic and Rich in Cysteines) has
been associated with a family of non-structurally related proteins
like Tenascin and Thrombospondin that regulate cell adhesion by
inducing focal cell contacts disassembly [12]. SPARC, also named
Osteonectin, is a secreted glycoprotein whose expression in healthy
tissues is largely associated with tissue remodeling, morphogenesis,
and wound healing [13]. In adults, its expression is greatly
diminished and restricted to areas with certain levels of cellular
turnover such as gut epithelia and central lens epithelia, Leydig
cells and Sertoli cells [13–15]. SPARC is produced by different cell
types including malignant cells and tumor associated stromal cells
such as fibroblast and endothelial cells [16]. It was found to bind to
different components of the extracellular matrix such as collagens,
and to interact with specific growth factors or with their signaling
pathways such as VEGF, PDGF and bFGF, suggesting that it
might play a role in vasculogenesis [17]. Among the many
biological processes modulated by SPARC, its anti-adhesive
[18,19], pro-migratory [20], and anti-apoptotic [21] properties
on certain cell types in addition to its capacity to regulate matrix
metalloproteinase (MMP) expression and activity [17,22,23] have
been associated with increased tumor agresiveness. Indeed,
increased SPARC expression has been described in multiple
cancers, including colon [24], esophagus [25], pancreas [26],
breast [27], lung [28], brain [29], bladder [30], renal [31], and
melanoma [18,32]. SPARC overexpression by the malignant cells
themselves or by neighbor fibroblasts and endothelial cells has
been associated with poor prognosis in different human cancer
types [16,33,34]. Primary and metastatic melanoma samples
expressed high levels of SPARC in malignant cells and in
intermingled fibroblasts and endothelial cells, whereas dysplastic
nevi, benign nevi and normal melanocytes exhibited low to none
SPARC expression [32]. Moreover, SPARC expression by
peritumoral fibroblasts portends a poorer prognosis for patients
with pancreatic cancer [33].
Reports characterizing the 59 region of the SPARC gene,
including the non-translated exon 1, revealed a significant
homology between the murine, bovine and human gene, including
the lack of canonical TATA or CAAT box sequences and the
presence of a purine-rich stretch composed of two boxes, named
GGA-box 1 and 2 separated by a 10 bp pyrimidine-rich spacer
element [35]. The GGA1 box provides maximal promoter
activity, and deletion of the spacer element appears to increase
the activity induced by the GGA boxes [35]. Interestingly, the
region comprising approximately 1.4 Kb that includes both GGA
boxes was suggested to be essential for cell-type specific regulation
of the bovine promoter but not of the human promoter [36]. This
difference might arise from a GC-box with multiple Sp1 binding
sites located upstream of the GGA-boxes in the bovine promoter
which is not conserved in the human promoter [36]. More recent
data observed with the human promoter demonstrated the
presence of an non-canonical AP1-binding site between
2120 bp and 270 bp that can bind a c-Jun/Fra1 heterodimer
in vitro [37]. This c-Jun responsive element is an SP-1 binding site
and appears to be sufficient to induce maximal promoter
activation [37]. We have recently shown that a 1.3 Kb SPARC
promoter fragment was effective in driving the expression of the
Herpes Simplex virus thymidine kinase gene (TK) both in
melanoma and endothelial cells leading to the elimination of
melanoma tumors in vivo in nude mice [38]. These data led us to
hypothesize that SPARC promoter could be a good candidate for
generating a CRAd to target the malignant and stromal cell
components of the tumor mass that will be strongly attenuated in
normal, non-cancer associated cells.
Here, we show that the oncolytic efficacy of these novel CRAds
depends on the specific interactions that the malignant cells
establish with neighbor stromal cells. This interaction might
restrict or augment CRAds efficacy depending on the tumor type.
We also propose that the design of CRAds should consider stromal
cells as a potential target for achieving improved efficacy.
Results
Selection of a SPARC promoter fragment to drive E1A
gene expression
In order to target both the tumor and stroma compartment we
designed a CRAd based on the SPARC promoter since SPARC
was shown to be expressed both in malignant and tumor-
associated stromal cells [16]. We first assessed the activity of
different promoter fragments that were generated maintaining the
integrity of specific motives such as two GGA boxes that confer
maximal activity, a TATA-like box, two transcription initiation
sites [35] and a putative downstream promoter element (DPE
[39]). Promoter activity was assessed by cloning each fragment
into the promoterless firefly luciferase reporter plasmid pGL3-
Basic followed by cell transfection and luminescence quantifica-
tion. By comparing luciferase levels in A375N melanoma cells that
overexpress SPARC compared to breast cancer T-47D and
cervical cancer HeLa cell lines that exhibited very low levels of
SPARC (see Table 1 for relative SPARC mRNA levels in different
cell lines), we selected the 2513/+35 fragment, and named it
F512Pr (Figure 1A). F512Pr showed 3.3-fold higher activity than
Table 1. Relative expression of SPARC mRNA levels in
different malignant and non-malignant cell lines.
Cell Line Source Relative Expression
a n
b
A375N Melanoma 100.00 3
MEL888 Melanoma 15.2360.61 3
MEL-J-N Melanoma 23.6562.97 3
SB2 Melanoma 31.2068.11 3
IIB-MEL-LES Melanoma 7.3660.58 3
BxPC3 Pancreas cancer 0.0060.00 2
MIA PaCa-2 Pancreas cancer 0.0060.00 3
T-47D Breast cancer 0.1560.04 3
MCF-7 Breast cancer 0.0060.00 2
MDA-231 Breast cancer 0.0060.00 2
NHM Normal melanocytes 8.0064.42 2
CCD841 Normal colon 4.0361.12 3
MCF12-A Normal breast 0.0060.00 2
HMEC-1 Human endothelium 20.2361.21 4
HaCaT Keratinocyte 0.0560.05 2
CCD1140 Fibroblast 41.7066.09 4
Malme-3 Fibroblast 78.0064.60 2
WI-38 Fibroblast 19.4761.67 3
aThe data was obtained by real time – PCR and is expressed as the relative
expression with respect to the levels observed in the A375N cell line. The
numbers correspond to the mean6standard deviation.
bNumber of replicates.
doi:10.1371/journal.pone.0005119.t001
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similar or less activity than the SV40 promoter (Figure 1A).
F512Pr exhibited the highest luciferase activity (1.7 to 4.9 - fold
induction over SV40 promoter) in melanoma cell lines that do
express high SPARC mRNA levels although no strict relationship
was observed between SPARC mRNA levels and promoter
activity (Figure S1A and Table 1). We were unable to efficiently
transfect additional non-malignant stromal cells such as WI-38
fibroblasts and HMEC-1 endothelial cells (data not shown).
CRAds cytopathic effect on malignant cells
Since stromal cells were hardly transfectable and the activity of
the promoter might change in the context of a viral structure, we
initially constructed a non-replicative adenoviral vector (Ad(I)-
F512-luc) where luciferase activity was driven by the F512Pr. All
the cell types tested, including fibroblasts and endothelial cells
exhibited promoter activity; in some cases higher than those
observed in malignant cells (Figure S1B). Based on this preliminary
evidence we constructed two new CRAds based on F512Pr. Ad-
F512 contained F512Pr upstream of the E1A gene (Figure 1B).
Ad(I)-F512-TK contained an insulator element [40] that isolated
F512Pr-E1A from the enhancer elements located in the left ITR,
and the TK suicide gene that was placed downstream of E1A
following an IRES sequence (Figure 1B).
The cytopathic effect (CPE) of the two CRAds was compared
on a panel of tumor cells that expressed or not SPARC mRNA.
Different human malignant cell lines were infected with different
concentrations of the CRAds or adenovirus wild type (Ad-wt) that
was used as a control for viral replication and lytic effect that was
assessed by crystal violet staining followed by densitometer
quantification. Initial experiments were performed in the absence
of GCV to test whether addition of the TK gene could be
deleterious to CRAd activity. Ad-wt exhibited CPE on almost
every cancer cell line at a low titer of 5610
4 (MOI of 1) to
5610
6 vp/ml (MOI of 100) regardless of SPARC expression levels
(Figures 2A and S2A). On the contrary, both CRAds exhibited
CPE mainly on SPARC positive-human melanoma cells at
relatively moderate viral concentrations of 5610
6 to
Figure 1. Luciferase activity driven by different variants of SPARC promoter. (A) Left: the different variants of SPARC promoter. Right:
Luciferase activity of the different variants of SPARC promoter different cells lines. Data are shown relative to SV40 luciferase activity. Error bars
represent mean6SD. (B) Schematic structure of Ad-F512 and Ad(I)-F512-TK genomes.
doi:10.1371/journal.pone.0005119.g001
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7 vp/ml (Figures 2A and S2A). It was of note that high
concentrations of the CRAds exerted a lytic effect on SPARC-
negative MIA PaCa-2 cells (Figure 2A and Table 1). By using E4
production as readout of viral replication we confirmed that the
CRAd replicated not only in SB2 melanoma cells but also in MIA
PaCa-2 pancreatic cancer cells (Figure S3). The importance of
CRAd replication in SPARC-negative cells is described below. In
general, Ad(I)-F512-TK exhibited increased CPE compared to
Ad-F512 and addition of GCV, not before 48 hr after viral
infection, enhanced its lytic activity indicating that the TK gene
was active (Figures 2B and S2B).
Lack of CRAds cytopathic effect on normal cells
We next established the level of attenuation of Ad-F512 and
Ad(I)-F512-TK lytic activity on normal cells. By day 10 following
infection with 5610
7 vp/ml of Ad-F512 or Ad(I)-F512-TK, the
viability of normal melanocytes was .95% compared to complete
melanocytes elimination by Ad-wt (Figure 3A). Similarly, Ad-F512
and Ad(I)-F512-TK exhibited no CPE on CCD841 normal
colonic cells or normal MCF12A breast cells, whilst Ad-wt lysed
these cells at 5610
6 vp/ml (Figures S4A and B). Moreover,
HaCaT keratinocytes were sensitive to the lytic effect of Ad-wt
while they were completely refractory to the lytic activity of
F512Pr-based CRAds (Figure 3B and S4C). Finally, the SPARC-
positive CCD-1140 and Malme-3 normal adult skin fibroblasts
were sensitive to the highest Ad-wt concentration but were
completely resistant to Ad-F512 or Ad(I)-F512-TK probably due
to the absence of E1B region in the present CRAd constructs [41]
(Figure 3B and S4C). These data demonstrate that normal cells are
completely resistant to the F512Pr-based CRAds regardless of
whether they expressed SPARC or not.
CRAds cytopathic effect on transformed endothelial cells
and fetal fibroblasts
We next assessed CRAd’s CPE on SPARC-positive large T
antigen-transformed microendothelial cells (HMEC-1) and WI-38-
fetal lung fibroblasts that could be considered as resembling the
potential characteristics of cancer-associated stromal cells. Both
cell types were lysed by Ad(I)-F512-TK in the absence of GCV
(Figures 3C and S4C) although WI-38 cells were at least one order
Figure 2. CRAd lytic activity in vitro on human cancer cells. (A) Cell viability after infection with Ad-wt, Ad-F512, or Ad(I)-F512-TK. Human
cancer cell lines were infected at different concentrations of the CRAds. (B) Viability of SB2 melanoma cells after infection with Ad-(I)F512-TK in the
presence or not of GCV added at the indicated times. Remaining cells were fixed and stained with crystal violet at day 10.
doi:10.1371/journal.pone.0005119.g002
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was probably the result of their higher transducibility compared to
WI-38 fibroblasts as assessed through the use of a non-replicative
adenovirus expressing luciferase (Figure S5). In fact, both cell types
were slightly permissive to viral replication compared to malignant
cells (Figure S3). Addition of GCV improved Ad(I)-F512-TK lytic
capacity on HMEC-1 cells, as assessed by the MTT assay
(Figure 3D). Similar studies with WI-38 cells evidenced no
improvement of CRAd activity (data not shown). Thus, SPARC-
positive HMEC-1 endothelial cells supported viral replication and
were sensitive to their cytotoxic activity.
The presence of stromal cells restricted the therapeutic
efficacy of the CRAds on established melanomas
Having established the lytic efficacy of the CRAds on the
different cell types, we next decided to examine the ability of Ad-
F512 to inhibit the growth of human melanoma xenografts s.c.
established in nude mice following administration of malignant
cells alone or mixed with stromal cells. Mice carrying established
SB2 melanoma tumors were treated with three consecutive i.t.
administrations at days 0, 3 and 7 of 10
10 vp/mouse of Ad-F512,
Ad-b-gal or vehicle alone. None of the mice benefited from the
administration of Ad-b-gal or vehicle as all the tumors reached
2c m
3 when mice were considered not survivors (Figure 4A and
Figure S6). Treatment with Ad-F512 resulted in a potent
antitumor effect, as the tumor completely disappeared in 3 of 5
mice and one mouse exhibited reduced tumor growth (Figure 4A).
One mouse remained alive for almost one year (data not shown).
Another mouse exhibited accelerated tumor growth, most
probably due to incomplete transduction and/or viral dissemina-
tion [42]. In two additional studies, 2/4 and 3/5 mice treated with
Ad-F512 remained free of tumor at the end of the experiments at
90 days (Figures 6SA and B). Cured mice exhibited complete
tumor remission 2–3 weeks after the last CRAd administration
(Figure 4B) that was accompanied by a massive macrophage
infiltrate probably associated with clearance of cellular debries
(data not shown). Tumor injection with Ad-b-gal showed staining
preferentially at the tumor periphery with a gradual decrease
towards the inner part of the tumor (Figure 4B). Thus, a CRAd
driven by the SPARC promoter was therapeutically effective
Figure 3. Assesment of CRAd lytic activity in vitro on non-cancerous human cells. (A) Lysis of normal melanocytes by Ad5-wt but not by
the CRAd. (B) HaCaT adult kerantinocytes and normal adult fibroblasts sensitivity to Ad-wt but not to the CRAds. (C) Lytic activity of the Adwt and
the CRAd on WI-38 fibroblasts and HMEC-1 cells (Of note is that HMEC-1 cells detached from the well in the absence of virus). (D) Reduced HMEC-1
viability after infection with Ad-(I)F512-TK (5610
6 vp/ml) followed by GCV. Remaining viable cells were stained as described. ***P,0.001 (one-way
ANOVA follow by a Tukey multiple comparison test).
doi:10.1371/journal.pone.0005119.g003
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melanomas composed of malignant cells alone.
To better understand the role of stromal cells we next studied
whether Ad-F512 could be therapeutically effective on established
tumors composed of melanoma and stromal cells. Mice were
xenografted with a mix of 4.0610
6 SB2 melanoma cells and
2.0610
6 WI-38 fetal fibroblasts (Mel/Fib tumors, Figure 4C).
Mel/Fib tumor’s architecture closely resembled human tumors
with nests of malignant cells separated by septa of fibroblasts
(Figure 4D) compared to the homogeneous appearance of tumors
made of malignant cells alone (see Figure 4B, b-galactosidase). In
the presence of WI-38 fibroblasts, Ad-F512 exerted a statistically
significant delay on Mel/Fib tumor growth but no cure was
observed (Figure 4C). Interestingly, only malignant cells at the
peripheral nests, but almost no WI-38 fibroblasts, were infected, as
evidenced by positive staining for b-gal activity (Figure 4D, b-
galactosidase). Malignant cells also showed positive hexon staining
after Ad-F512 administration, indicating viral replication
(Figure 4D, hexon staining).
We further examined the role of stromal cells by xenografting
mice with a mix of 4.0610
6 SB2 cells and 2610
6 HMEC-1 cells
(Mel/Endo tumors, Figure 4E). Nests of HMEC-1 distributed all
over the tumor mass exhibiting cobblestone morphology
(Figure 4F, cobblestone morphology), and few of them that
Figure 4. Ad-F512 effect on the in vivo growth of human melanoma xenografts. (A) Tumor growth in mice harboring SB2 melanomas
treated with Ad-F512 or control virus. Right panel shows Kaplan-Meier survival curves. (B) Left panel includes photographs of an Ad-b-gal – treated
mouse and a mouse treated with the CRAd. The arrow shows complete tumor regression, 14 days after Ad-F512 administration. (C) Tumor growth in
mice harboring Mel/Fib tumors treated with Ad-F512 or control virus. Right panel shows Kaplan-Meier survival curves. (D) Left panel shows Mel/Fib
tumors staining positive for b-galactosidase in the malignant nests but not in fibroblasts septa (arrow), and right panel shows adenoviral hexon-
positive staining of Mel/Fib tumors. (E) Tumor growth in mice harboring Mel/Endo tumors treated with Ad-F512 or control virus. Right panel shows
Kaplan-Meier survival curves. (F) Left panel includes nests of microendothelial cells with the typical cobblestone morphology; middle panel shows
endothelial cells staining positive for Von Willebrand and right panel shows Mel/Endo tumors staining positive for b-galactosidase both in malignant
cells and in endothelial cells lining intratumor vessels (arrow). In figures corresponding to the in vivo studies, each curve corresponds to a single
animal.
doi:10.1371/journal.pone.0005119.g004
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endothelial differentiation (Figure 4F, Von willebrand factor
staining). Interestingly, both melanoma and endothelial cells
surrounding blood vessels stained positive for virus infection
following administration of Ad-b-gal (Figure 4F, b-galactosidase).
Thus, despite the absence of a clear physical barrier for viral
spreading in Mel/Endo tumors, the presence of endothelial cells
impaired Ad-F512 activity as WI-38 did, and no cure was
observed.
Given the reduced therapeutic efficacy of Ad-F512 in the
presence of stromal cells, we sought to establish whether TK
expression combined with GCV might help to overcome tumor
resistance due to the presence of stromal cells in the tumor mass.
Thus, mice harboring Mel/Endo tumors were treated with Ad(I)-
F512-TK followed by 2 weeks of GCV administration. GCV
started to be administered 4 days after the last viral injection to
facilitate maximal viral spreading and to avoid cell death induced
by GCV before the virus started replicating. Under these
conditions, 5 out of 6 mice showed tumor growth delay after
treatment with Ad-(I)F512-TK and GCV including one tumor
that ceased growing compared to none in control mice (Figure 5A).
Similar experiments performed on established Mel/Fib tumors
showed inhibition of growth with Ad-(I)F512-TK/GCV in all
mice compared to the control, and complete remission in 2 mice
(Figure 5B). Thus, Ad-(I)F512-TK/GCV demonstrated improved
efficacy compared to Ad-F512 since few cures were observed after
treatment, although as a whole, the presence of stromal cells
hampered viral lytic efficacy.
The presence of stromal cells improved the therapeutic
efficacy of the CRAd on established pancreatic cancer
Figure 2A showed that the CRAds exerted a lytic effect on MIA
PaCa-2 cells despite the absence of SPARC expression. Previous
studies have shown that SPARC promoter is hypermethylated in
pancreatic cancer cells [26]. That should not necessarily affect the
activity of an extrinsic promoter carried by the CRAd. Indeed
F512Pr was able to drive luciferase expression in the context of an
adenoviral vector in MIA PaCa-2 cells, although at a lower level
compared to A375N melanoma cells (Figure S7). Based on that,
we assessed whether the present CRAd may be active on SPARC-
negative pancreatic cancer cells in vivo in the presence or not of co-
administered stromal cells.
Treatment of established MIA PaCa-2 tumors made of
malignant cells alone with Ad(I)-F512-TK+GCV induced remis-
sion of 2 out of 7 tumors while the other 5 grew as the controls
although this difference was not statistically significant (Figure 6A).
This suggests that SPARC promoter was partially active on
pancreatic cancer despite the lack of SPARC expression. We next
treated mice harboring tumors made of an initial mix of 9.0610
6
MIA PaCa-2 cells and 2.0610
6 HMEC-1 cells (Pan/Endo
tumors). We selected HMEC-1 cells over WI-38 fibroblasts based
on their higher infectivity in vitro and in vivo and their capacity to
inhibit the in vitro growth of a co-culture of HMEC-1: MIA PaCa-2
cells when HMEC-1 cells were pre-infected with Ad(I)-F512-TK
in the presence of GCV (Figure S8).
Pan/Endo tumors showed loosely packed malignant cells
surrounded by a dense extracellular matrix that was independent
of the presence or not of HMEC-1 cells (Figure 6B). Pancreatic
tumors obtained without endothelial cells showed a similar
morphology (data not shown). In order to confirm that HMEC-
1 cells were present in the tumor mass at the time of CRAd
infection we pre-infected them with a lentivirus expressing GFP.
Microscopic observation of tumor slices confirmed the presence of
EGFP-positive cells that in some cases formed typical cobblestone
structures (Figure 6C), and tend to form vessels that often stained
positive for factor VIII (Figure 6D). Ad(I)-F512-TK administration
followed by GCV induced complete tumor remission in all but one
mice (5/6) strongly indicating that the presence of HMEC-1
microendothelial cells in the pancreatic tumor mass favored the
therapeutic efficacy of Ad-(I)-F512-TK/GCV (Figure 6E).
Soluble factors produced by stromal cells greatly
influence viral oncolytic efficacy
The striking differences in CRAd activity observed between
melanoma and pancreatic cancer when microendothelial cells
were co-administered with malignant cells and the evidence that
microendothelial cells and fibroblasts hampered CRAd activity
irrespective of tumor architecture, led us to hypothesize that
Figure 5. Ad(I)-F512-TK+GCV effect on the in vivo growth of human melanoma xenografts including stromal cells. (A) Tumor growth
and Kaplan-Meier survival curve of mice harboring Mel/Endo tumors, treated with Ad(I)-F512-TK or vehicle, followed by GCV. (B) Tumor growth and
Kaplan-Meier survival curve of mice harboring Mel/Fibro tumors treated with Ad(I)-F512-TK or vehicle followed by GCV. Each curve represents a single
animal.
doi:10.1371/journal.pone.0005119.g005
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HMEC-1-conditioned media induced a slight inhibition of F512Pr
activity in SB2 melanoma cells (Figure 7A). In clear contrast, both
WI-38 and HMEC-1 conditioned media strongly enhanced
F512Pr activity in pancreatic MIA PaCa-2 cancer cells
(Figure 7A). In addition, WI-38-conditioned media enhanced
viral lytic activity on SB2 cells and other melanoma cells as well
(Figure 7B and S9A). Moreover, both conditioned media
enhanced at a different extent CRAd activity on MIA PaCa-2
cells (Figures 7B and S9A).
Surprisingly, preinfection of stromal cells with the CRAd
completely obliterated the enhancement in CRAd lytic activity
induced by the conditioned media on SB2 melanoma cells
(Figure 7C). But in clear contrast, conditioned media obtained
from pre-infected HMEC-1 and WI-38 cells dramatically
enhanced CRAd lytic activity on MIA PaCa-2 cells (Figure 7C).
This effect was observed even at 1/5000 dilution indicating its
potency (Figure S9B). Thus, soluble factors produced by stromal
cells can play a dramatic and differential role in defining the
therapeutic efficacy of a CRAd on specific tumor types.
Soluble factors produced by stromal cells enhance
pancreatic cancer cells exit from quiescence
Previous evidence demonstrated that oncolytic viruses increased
the amount of cells in S-phase [43] and that E1B mutant viruses,
such as the present CRAds, exhibited better cytopathic effect on
cells in S phase [44]. To dissect CRAd’s effects, we first assessed
whether arrested malignant cells infected with the CRAd showed
an accelerated exit from quiescence compared to non-infected
cells. Indeed, infected MIA PaCa-2 cells exhibited a higher cell
number in S-phase at 20 hr compared to non-infected cells
(Figure 8A). Surprisingly, SB2 melanoma cells exhibited a retarded
exit from G0/G1 compared to MIA PaCa-2 cells, regardless of
whether SB2 cells were infected or not with the CRAd (Figure 8A).
Next, we assessed whether stromal cells-conditioned media
might also accelerate MIA PaCa-2 cells exit from quiescence.
Twenty four hours after MIA PaCa-2 cells release from G0/G1,
we observed a clear increase in the amount of cells in S-phase
when they were exposed to conditioned media obtained from
HMEC-1 cells pre-infected with the CRAd (Figure 8B), compared
to MIA PaCa-2-own conditioned media obtained from cells
infected also with the CRAd (Figure 8B) or the control media
(Figure 8B).
Discussion
This work provides the first evidence on the key role that
stromal cells play in the outcome of the oncolytic efficacy of
conditionally replicative adenoviruses. To our surprise the
presence of stromal cells was detrimental for CRAd efficacy on
melanoma tumors but favored CRAd oncolytic activity on
pancreatic tumors. Soluble factors secreted by stromal cells were
Figure 6. Ad(I)-F512-TK+GCV effect on the in vivo growth of human pancreatic cancer xenografts. (A) Tumor growth and Kaplan-Meier
survival curve of mice harboring MIA PaCa-2 tumors, treated with Ad(I)-F512-TK or vehicle, followed by GCV. (B) Hematoxylin-eosin staining of Pan/
Endo tumors; the area limited by the square is enlarged in D. (C) Typical nests of microendothelial cells (EGFP-HMEC-1) with cobblestone morphology
in a Pan/Endo tumor. (D) Large and small vessels (arrow) staining positive for Von Willebrand factor. (E) Tumor growth and Kaplan-Meier survival
curve of mice harboring Pan/Endo tumors, treated with Ad(I)-F512-TK or vehicle, followed by GCV. Each curve represents a single mouse. Error bars
represent mean6SD.
doi:10.1371/journal.pone.0005119.g006
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explain this differential efficacy: the levels of viral lytic activity and
the timing for cell exit from quiescence. Thus, either because they
hampered or enhanced CRAd activity, stromal cells might play an
important role in defining the maximal oncolytic capacity of these
viruses.
We designed conditionally replicative adenoviruses based on a
specific segment of the SPARC promoter with the aim to target
both malignant and tumor-associated stromal cells. Either CRAd,
expressing or not TK were cytotoxic in vitro on a panel of
melanoma cell lines expressing SPARC. Mostly important, normal
cells from diverse sources were completely refractory to the
CRAds while under the same conditions they were eliminated by
wild type Ad5. Of note, Ad-F512 and Ad(I)-F512-TK were unable
to lyse normal adult fibroblasts while exhibited lytic effect on cells
that resemble cancer-associated stromal cells such as transformed
microendothelial cells and fetal fibroblasts.
We observed a clear therapeutic efficacy of our CRAds on
melanoma tumors made of malignant cells alone. Although the
CRAd expressing TK appeared to exhibit a slightly enhanced
therapeutic efficacy both CRAds exhibited diminished efficacy
when tumors contained in addition stromal cells. Co-administra-
tion of WI-38 fibroblasts imposed to melanoma tumors an
architecture consisting of malignant cell nests separated by
fibroblasts septa that appeared as a physical barrier for the
CRAds and were refractory to viral infectivity in vivo. Previous
studies suggested that the presence of physical barriers produced
by stromal cells or their increased production of extracellular
matrices imposed restrictions for viral spread and hence,
diminished viral therapeutic efficacy [42,45]. These physical
barriers also appeared to restrict viral infection to malignant cells
in close proximity to blood vessels [46]. Therefore, co-adminis-
tration of proteolytic enzymes that degrade the ECM or the use of
vasoactive compounds were proposed as alternatives to improve
the therapeutic efficacy of oncolytic viruses [11,47] with the risk of
releasing malignant cells to the circulation. While it is likely that
the presence of WI-38 cells could hamper viral spread, it was
surprising that the presence of HMEC-1 also restricted viral
efficacy although no histological evidence of a physical barrier was
observed. On the contrary, soluble factors secreted by WI-38
fibroblasts, but not HMEC-1 endothelial cells, exerted a slight but
significant enhancement of CRAd activity on melanoma cells in
vitro that was obliterated when the conditioned media was obtained
from pre-infected WI-38 cells. In this regard it was of interest that
Figure 7. Effect of conditioned media produced by stromal cells on CRAd activity. (A) Transcriptional activity of F512Pr in SB2 and MIA
PaCa-2 cells following cell infection with Ad(I)-F512-luc in the presence of HMEC-1 (column E), WI-38 (column F)- or their own conditioned medium
(column C). (B) Cell viability after infection of SB2 and MIA PaCa-2 cells with Ad(I)-F512-TK in the presence of the different conditioned media. (C). Cell
viability after infection of SB2 and MIA PaCa-2 cells with Ad(I)-F512-TK in the presence of the different conditioned media obtained from previously
infected cells. *P,0.05, ***P,0.001 (one-way ANOVA follow by a Tukey multiple comparison test).
doi:10.1371/journal.pone.0005119.g007
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on Mel-Endo tumors, suggesting that soluble factors produced by
non-infected WI-38 cells might have enhanced CRAd activity in
vivo. Although highly unlikely, we cannot rule out that host cells
could have contributed in some aspects to the results since the
F512 human promoter is active in rodent fibroblasts in vitro (data
not shown).
It was not unexpected that the present CRAds were also slightly
effective on SPARC-negative pancreatic cancer cells. Previous
evidence has shown that promoters carried by the CRAd are not
subjected to the transcriptional regulations imposed to endogenous
promoters such as hypermethylation [48]. More striking was the
evidence that co-administration of endothelial cells enhanced the
therapeutic efficacy of the CRAd in pancreatic tumors. This was
consistent with the fact that soluble factors produced by fibroblasts
and microendothelial cells enhanced viral activity in pancreatic
cancer cells, especially when conditioned media were obtained
from pre-infected cells. Previous evidence from the literature have
demonstrated that oncolytic viruses increased the amount of cells
in S-phase [43]. Even more important, E1B mutant viruses, such
as the present CRAds, exhibited better cytopathic effect on cells in
S phase [44]. The present work indicates that the CRAd
accelerates pancreatic cancer cells exit from quiescence and
induces the release of soluble factors produced by stromal cells that
enhance the number of pancreatic cancer cells in S-phase. Both
effects might converge in an enhanced lytic effect compared to
melanoma cells. Thus, despite the fact that adenoviruses are
known for their capacity to infect cycling and non-cycling cells, our
data suggest that non-cycling cells could avoid CRAd attack. This
is especially important since a consensus exists that potential
cancer stem cells are not cycling under steady state conditions.
Thus, the identification of the soluble factors produced by stromal
cells that can accelerate G0/G1 exit of malignant cells could be
very useful to design improved vectors or as potential adjuvant of
virotherapy. In preliminary experiments using neutralizing
antibodies we identified the mitogenic factor bFGF as one the
products present in stromal cells-conditioned media, supporting
the idea that accelerated release of malignant cells from quiescence
could be used as adjuvancy. In this regard, recent evidence
demonstrate that lentiviral vectors that, similar to adenoviruses,
were supposed to infect both cycling and quiescent cells appear to
be more effective in the presence of mitogenic factors such as EGF
[49] supporting the idea that the induction of cell reentry from
quiescence could provide a better scenario to enhance CRAd
effectiveness.
The potential clinical use of an oncolytic vector based on
SPARC promoter raised the question as to whether downregu-
lation of SPARC expression might serve as an escape mechanism
for a cell to avoid oncolytic attack. The role of SPARC in tumor
progression is controversial although in certain types of human
cancer such as glioblastoma and melanoma, SPARC overexpres-
sion in the malignant cells themselves has been associated with
Figure 8. Effect of conditioned media produced by stromal cells on cell cycle. (A) Exit from cell cycle quiescence of MIA PaCa-2 and SB2
cells pre-infected with the CRAd. (B) Exit from cell cycle quiescence of MIA PaCa-2 cells in the presence of different conditioned media. One biological
replicate out of two is shown in each case.
doi:10.1371/journal.pone.0005119.g008
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ly, SPARC overexpression by tumor-associated fibroblasts in
pancreatic and lung cancer is also a marker of bad prognosis
despite the fact that the malignant cells themselves are SPARC-
negative due to promoter hypermethylation [33,50]. Based on the
present data we might hypothesize that if cell clones that are
SPARC-negative due to promoter hypermethylation emerge due
to the selective pressure imposed by CRAd attack, they might be
still susceptible to the treatment if the DNA binding proteins that
regulate SPARC promoter activity are being expressed. Alterna-
tively, malignant SPARC-negative cells such as those found in
pancreatic cancer might be susceptible to oncolytic attack if they
are surrounded by stromal SPARC-positive cells. In this regard, a
very recent article also raised the possibility to overcome the
barrier imposed by cancer associated fibroblasts by using selected
mutant viruses with enhanced capacity to replicate in cancer
associated stromal cells [51]. Indeed, multiple passages in vivo of a
wild type adenovirus 5 in a human pancreatic tumor xenografted
in nude mice selected a mutant virus with enhanced antitumor
activity and augmented lytic effect and progeny release both in
malignant cells and in cancer associated fibroblasts [51].
Adenoviral retargeting through partial or complete modification
of the fiber, has become a method of choice to improve viral
efficacy [52]. We observed that melanoma/stroma xenografts
grew faster than xenografts of melanoma cells alone (see control
groups in Figure 4) indicating the need for improved viral
infectivity since human tumors are a heterogeneous mix of
malignant and stromal cells. It has been shown that stable
melanoma cell lines express CAR, while short term cultures of
primary melanomas very often lack CAR expression [52]. Primary
melanomas were very efficiently transduced by other adenovirus
serotypes or by pseudotyped particles with chimeric or genetically
modified fibers [52–54]. However, tumor endothelium appears to
be very efficiently infected by adenovirus type 5 [55]. Thus, deeper
knowledge of the in vivo expression of viral receptors in the
different cellular compartments of the tumor mass (malignant and
stromal cells) might help improve the therapeutic efficacy of
virotherapy.
Stromal cells are a major component of human cancer tissue
and ‘‘cross talk’’ with malignant cells to stimulate tumor growth
and metastatic dissemination. We believe that their co-adminis-
tration in murine models of cancer is essential to better understand
viral spread and oncolytic efficacy. As we show here, they can
support viral replication and modulate the efficacy of a CRAd
through the production of soluble factors. Testing additional
CRAds that target only malignant cells or using non-permissive
stromal cells in mixed models as the one described in this article,
would be useful to establish whether targeting stromal cells can
definitely improve the in vivo antitumor efficacy of oncolytic
vectors.
Materials and Methods
Cell Culture
The human cell lines HeLa (cervical cancer, CCL-2), T-47D
(breast cancer, HTB-133), MDA-MB-231 (breast cancer, HTB-
26), WI-38 (fetal lung fibroblasts, CCL-75), MCF-7 (breast cancer,
HTB-22), MIA PaCa-2 (pancreas carcinoma, CRL-1420), BxPC-3
(pancreas adenocarcinoma CRL-1687), Malme 3 (normal skin
fibroblast, HTB-102), CCD-1140 (normal skin fibroblast, CRL-
2714), CCD841 (normal colon, CRL-1790), MCF12A (normal
breast, CRL-10782), and 293HEK (human embryonic kidney,
CRL-1573) were obtained from ATCC (American Tissue Culture
Collection, Rockville, MD, USA). The HMEC-1 cells (Human
Microvascular Endothelial Cells) were kindly provided by
Francisco Candal (Atlanta, USA). The human melanoma cell line
IIB-MEL-LES was already described [18]; MEL-J-N is an in vitro
selected clone of IIB-MEL-J [18]; A375N, MEL888 and SB2
human melanoma cell lines and human normal melanocytes were
kindly provided by Estela Medrano (Houston, USA). Keratino-
cytes (HaCaT) were kindly provided by Fernando Larcher
(Madrid, Spain). All the cell lines were grown in the recommended
medium supplemented with 10% of fetal bovine serum (Natocor,
Cordoba, Argentina), 2 mM glutamine, 100 U/ml penicillin and
100 mg/ml streptomycin and maintained in a 37uC atmosphere
containing 5% CO2. MIA PaCa-2 cells were also supplemented
with 2.5% of horse serum (Invitrogen, Carlsbad, CA).
Plasmids and recombinant adenoviruses
pGEM-hSPPr plasmid containing the 21175/+71 SPARC
promoter [38] was used as a template to obtain the SPARC
promoter variants displayed in Figure 1. Table 1S provides the list
of primers used for the different clonings: the 21175/+35
promoter fragment was cloned using primers SPfse and R35; the
21175/+28 promoter fragment using primers SPfse and R28, the
2513/+71 promoter fragment using primers F513 and R71, the
2513/+35 promoter fragment using primers F513 and R35, the
2513/+28 promoter fragment using primers F513 and R28
(Table S1), the 2513/+24 promoter fragment using primers F513
and R24, the 2120/+71 promoter fragment using primers F120
and Spas, the 2120/+35 promoter fragment using primers F120
and R35, and the 2120/+28 promoter fragment using primers
F120 and R28. The hSPPrD10 promoter variant (1236 bp) was
already described [38]. The different promoter variants were
cloned in pCR4-TOPO (Invitrogen, Carlsbad, CA) and sub-
cloned in the promoterless firefly luciferase reporter plasmid
pGL3-Basic (Promega Corp., Madison, WI).
In order to improve the shuttle vector-pADPSY capacity [56],
we replaced the RSV promoter with a multiple cloning site (MCS:
SpeI, BclI, KpnI, NheI, MluI, BglII, EcoRV, ClaI, SnaBI, SalI) to
create the pAd-Xp shuttle vector. Next, a fragment of 234 bp
corresponding to the stop codon region of the bovine growth
hormone gene [40] was PCR-cloned in the SpeI/KpnI sites
downstream of the ITR in the MCS to create a new shuttle
vector, pAd-I-Xp (using primers INSU-F-SpeI: INSU-R-KpnI,
Table S1). A BglII/BamHI-E1A gene fragment (+560/+1632 of the
adenoviral genome) was subcloned in the BglII site of pAd-Xp or
pAd-I-Xp followed F512 promoter cloning upstream of E1A in
MluI/BglII sites, to obtain the shuttle plasmids pAd-F512-E1A or
pAd-I-F512-E1A. The HSV-tk gene was amplified from the
plasmid phSPPr-TK ([38]) and cloned in NcoI/SalI sites of pCite-1
vector (Novagene, Madison, WI.). The fragment IRES-HSV-tk
was extracted with EcoRI and SalI, the EcoRI site was filled in and
cloned in pAd-I-F512-E1A in the EcoRV/SalI sites downstream of
E1A to obtain the pAd(I)-F512-TK plasmid.
In order to produce pAd-SV40-luc vector the SV40-luciferase
fragment was extracted from pGL3 with BglII/BamHI and cloned
in the BglII site of pAd-XP. pAd(I)-F512-luc was constructed in
two steps. First, the luciferase gene was obtained from pGL3-513/
+35 with BglII/BamHI and cloned in the BglII site of pAd-XP
vector to produce pAd-XP-luc. Next, the (I)-F512 sequence was
obtained from pAd-I-F512-E1A with FspI/BglII and cloned into
the FspI/BglII site of pAd-XP-luc to obtain pAd(I)-F512-luc.
Finally, the 2256 bp fragment of CMV-Renilla was obtained from
pRL-CMV (Promega Corp. Madison, WI) with BglII/BamHI and
subcloned in the BglII site of pAd-XP vector to create pAd-CMV-
Renilla. To construct Ad-F512, Ad(I)-F512-TK, Ad(I)-F512-luc,
Ad-CMV-Renilla and Ad-SV40-luc, the co-transfection in
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purification were performed as described [58]. Physical particle
concentration (viral particles/ml) was determined by absorbance
at 260 nm. Determination of 50% tissue culture infective dose-TC
ID50 was determined by standard plaque assay on 293HEK cells
[58]. All the constructs and viruses were confirmed by restriction
pattern and automatic DNA sequencing (ABI PRISM 377 DNA
Sequencer, Applied Biosystems, Foster City, CA). Ad-wt was
kindly provided by Dr Andre Lieber (Seattle, USA).
Luciferase Assays and Real Time-PCR
Luciferase assay using plasmids were performed as described
[38]. For assays using adenovirus, 5610
4 cells/well (seeded in 24-
well plates) were transduced with Ad-SV40-luc at 25610
6 vp/ml
in 200 ml of DMEM/F12 containing 2% FBS. Eight hundred mlo f
fresh medium containing serum was added 2 hours later followed
by cells harvesting 48 hours later. Quantification of luciferase
activity followed manufacturer’s recommendations (Promega
Corp. Madison, WI). Luciferase activity was normalized by
protein concentration in the cell lysate (Bio- Rad, Hercules, CA).
For assessing promoter activity in the presence of the different
conditioned media, cells were seeded in 24-well plates at a density
of 7610
4 cells/well. The next day, cells were infected with Ad(I)-
F512-luc (35610
6 vp/ml, about 100 of MOI) and Ad-CMV-
Renilla (3.5610
6 vp/ml, about 10 of MOI) in 200 mlo f2 %
DMEM/F12. After 2 hours of infection the medium was removed
and 0.4 ml of serum-free conditioned medium was added. Cells
were harvested 48 hours later and dual luciferase assay was
performed following manufacturer’s recommendations (Promega
Corp. Madison, WI).
Real Time-PCR was performed as described [38].
Cell killing assays
Cells were seeded in 24-well plates at a density of 1610
4 cells/
well (HMEC-1 density was 5610
4 cells/well). The next day, cells
were infected with the corresponding virus in 200 ml of DMEM/
F12 containing 2% FBS. After 4 hours of infection 0.8 ml of
fresh medium containing 10% FBS was added. Cytopathic effect
was monitored by staining viable cells with crystal violet [58].
For evaluation of Ad(I)-F512-TK activity followed by GCV, cells
were infected at 5610
6 pv/ml in 200 ml. Twenty four hours
later, cells were mixed and seeded onto a 24-well plate with
uninfected cells at density of 5610
4 cells/well. The next day,
cells were treated with 50 mM of GCV. The medium with GCV
w a sr e p l a c e de a c h4 8h o u r s .A f t e r5d a y so fe x p o s u r et oG C V .
The number of surviving cells was determined by the MTT assay
[59].
One step growth curves in malignant and stromal cells
SB2, MIA-PaCa-2, HMEC-1 and WI-38 cells (2610
4 cells/
well) were infected at 100 MOI of Ad(I)-F512-TK or inactivated
Ad(I)-F512-TK (heated during 20 minutes at 90uC) in 200 mlo f
DMEM/F12 containing 2% FBS. After 4 hr of infection medium
was removed, the cells were washed with PBS to remove
uninternalized viruses, and 0.5 ml of fresh medium containing
10% FBS was added. Cells were collected at time 0, 48 hr, 72 hr
and 96 hr later. DNA was extracted from cells using the Illustra
tissue & cells genomicPrep Mini Spin kit (GE Healthcare,
Buckinghamshire, United Kingdom) and E4 gene was measured
by Q-Real Time PCR [60,61]. Genomic DNA was subjected to
Real-Time PCR in an iCycler iQ System (Bio-Rad Laboratories,
Hercules, CA, USA). Each 25 ml reaction volume contained 1 unit
PlatinumH Taq DNA polymerase (Invitrogen, Carlsbad), 16PCR
Reaction Buffer (20 mM Tris–HCl, 21 pH 8.4, and 50 mM KCl),
1.5 mM Mg2Cl, 2.5 g BSA, 0.01% Glycerol, 0.4 mM of each
specific primer targeting the E4 region (Ad5, nucleotides 33806–
34074) (Table S1), 200 mM of dNTPs and 0.36SYBR Green
Solution. PCR conditions were set as follows: 150 seconds at 94uC
and then 39 cycles of 45 seconds at 94uC, 30 seconds at 60uC and
30 seconds at 72uC. All the reactions were performed in triplicate.
Analysis of data was carried out using the iCycler software (Bio-
Rad Laboratories, Hercules, CA, USA) by comparing test sample
to a standard. Standard Curves were generated by serial dilutions
of 10
10 copies of Adenoviral DNA in a solution of control cellular
genomic DNA. Total E4 copies per sample were normalized with
the amount of DNA present in each sample and reported as E4
copies/ng of DNA.
In vivo studies
Five to six - weeks old female athymic N:NIH(S)-nu mice
(Faculty of Veterinary, University of La Plata, Argentina) were
s.c. injected either with tumor cells alone or with a mix of tumor
cells and stromal cells. When the average tumor volume reached
100 mm
3, mice were randomly separated into different treat-
ments. The corresponding groups received three intra-tumoral
injections on days 0, 3 and 7, either of Ad-F512 or Ad(I)-F512-
TK containing 1610
10 vp/mouse. Control mice were injected
either with Ad-b-gal or vehicle indistinctly since both had no
effect on tumor growth. In the case of GCV treatment, four days
after the last adenovirus injection a daily dose of 30 mg kg
21 of
GCV (Cymevene, Roche) was administered for 15 consecutive
days. Tumor volumes were estimated weekly from caliper
measurements (volume=0.56(width)
26length). Mice were sac-
rificed when tumors reached an average of 2000 mm
3 and mice
were considered not survivors. None of the mice showed signs of
wasting or other visible indications of toxicity. In vivo experiments
followed institution guidelines, and all animals under study
received food and water ad-libitum.
GFP/HMEC-1 cells were obtained by infection of the
endothelial cells with a GFP-lentiviral virus (GenScripts Corp.,
Scotch Plains, NJ, USA). Cells (1610
5) were plated into each well
of a six-well plate and after 4 h infected with a multiplicity of
infection of 5 in the presence of 8 mg per mL of polybrene (Sigma,
St Louis, Missouri). Cells were incubated with the virus for 15 hr,
washed and examined for green fluorescent protein (GFP)
expression at 48 hr. After 48 hr antibiotic selection was initiated
and stably expressing GFP cells were selected.
For histology studies, samples were fixed in 10% neutral-
buffered formalin before paraffin embedding and cutting of 5-mm
sections. Alternatively, samples were fixed in 4% paraformalde-
hyde for 1 hour, cryopreserved overnight in 30% sucrose,
embedded in tissue OCT, and stored at 220uC. Cryostat sections
of 9 mm were mounted on gelatin-coated slides. After hydration
slides were hematoxylin and eosin stained. For immunohisto-
chemical studies we used a goat anti-adenoviral hexon protein
antibody AB1056 (Chemicon International, Hampshire, UK), a
rabbit anti-b-galatosidase antibody A-11132 (Molecular Probes,
Eugene, OR, USA) and a rabbit anti-human Von Willebrand
Factor (Dako, Germany) followed by a biotinylated donkey anti-
goat antibody (Jackson ImmunoResearch, West Grove, USA) or
biotinylated goat anti-rabbit antibody (Vector Laboratories,
Burlingame, CA, USA), respectively. Biotinylated secondary
antibodies were used in conjunction with the Vectastain ABC kit
(Vector Laboratories, Burlingame, CA, USA) and finally the
reaction was visualized with DAB (Dako, Germany). Slides were
counterstained with hematoxylin and photographed in an
Olympus BX60 microscope.
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Preparation of conditioned media
Four million cells were seeded on 100 mm cell culture dishes.
Twenty four hours later cells, infected or not with 500 MOI of the
CRAd, were placed in DMEM/F12 containing 2% FBS. Two
hours later, medium was replaced by DMEM/F12 without serum
and conditioning was followed for additional 24 hours, centrifuged
and stored at 280uC. The amount of virus in the conditioned
media was determined by 50% tissue culture infective dose (TC
ID50) in a standard plaque assay on 293HEK cells [58]. An
average of 10
7–10
8 vp/ml was found in all preparation.
Flow cytometry
Cells (2.5610
5/well MW6) were arrested in G0/G1 by serum
starvation for 72 hours and then kept in 1 ml of DMEM/F12
containing 2% FBS for two hours. Cells were infected or not at
1000 of MOI in the same medium. Four hours later, 2 ml of
serum-free conditioned medium was added and final serum
concentration was adjusted to 5%. Cells were trypsinized at the
indicated times, washed with PBS, fixed in 70% ethanol at 4uC
overnight, washed again with PBS, resuspended in PBS-triton-
X100, treated with RNase (Sigma Co, San Luis, MO) and stained
with propidium iodide. Cell cycle status was analyzed using a
FACSCalibur flow cytometer (Becton Dickinson, Oxford, United
Kinngdom). Ten thousand cells were analyzed in each case.
Statistical analysis
Survival rates were calculated with the Kaplan–Meier method
and differences were evaluated by the log-rank test. Statistical
difference between groups was determined by one-way analysis of
variance follow by a Tukey multiple comparison test. A P-value of
,0.05 was considered statistically significant. Data analysis was
performed with the GraphPad Prism 4.0 (GraphPad Software,
Inc., San Diego, CA).
Supporting Information
Figure S1 Luciferase activity driven by F512Pr. (A) In a plasmid
context. (B) In an adenovirus context. Transcriptional activity of
F512Pr promoter in stromal and malignant cells following
infection with Ad(I)-F512-luc/Ad-CMV-Renilla. Data are ex-
pressed in RLU (Firefly/Renilla). Error bars represent mean6SD.
Found at: doi:10.1371/journal.pone.0005119.s001 (5.58 MB EPS)
Figure S2 Quantification of Crystal violet assays. Densitometric
analysis of wells corresponding to figures 2A and 2B was performed
by using the Image J program available at http://rsb.info.nih.gov/ij;
and developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD. Error bars represent mean6SD.
Found at: doi:10.1371/journal.pone.0005119.s002 (1.07 MB
PDF)
Figure S3 One step growth curve and viral production. Time
dependent increase of E4 gene copy was used as a readout of
CRAd replication. (A) Cells infected with Ad(I)-F512-TK and (B)
Cells infected with heat-inactivated Ad(I)-F512-TK.
Found at: doi:10.1371/journal.pone.0005119.s003 (0.29 MB
PDF)
Figure S4 Cytophathic effect and quantification of Crystal violet
assays. (A) CPE of normal colon cells CCD841. (B) Cell viability of
normal breast cells MCF12A. (C) Densitometric analysis of wells
corresponding to Figures 3B and C was performed by using the
Image J program available at http://rsb.info.nih.gov/ij; and
developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD. Error bars represent mean6SD.
Found at: doi:10.1371/journal.pone.0005119.s004 (0.98 MB
PDF)
Figure S5 In vitro transduction of HMEC-1 and WI-38 cells
with non-replicative adenovirus. WI-38 and HMEC-1 cells were
transduced with 56106 vp/ml of Ad-SV40-luc as described in
Material and Methods. Cell extracts were assayed two days later
for firefly luciferase activity and protein concentration. Error bars
represent mean6SD.
Found at: doi:10.1371/journal.pone.0005119.s005 (0.27 MB
PDF)
Figure S6 Ad-F512 effect on the in vivo growth of human
melanoma xenografts. (A) and (B) Tumor growth in mice
harboring SB2 melanomas treated with Ad-F512, vehicle or
control virus (Ad-b-gal). Right panel corresponds to Kaplan-Meier
survival curve of the tumor growth graft.
Found at: doi:10.1371/journal.pone.0005119.s006 (0.38 MB
PDF)
Figure S7 Luciferase activity driven by F512Pr in melanoma
and pancreatic cancer cells. Transcriptional activity of F512Pr
promoter in MIA PaCa-2 and A375N cells following infection
with Ad(I)-F512-luc/Ad-CMV-Renilla. Data are expressed rela-
tive to Ad-SV40-luc activity in each cell line.
Found at: doi:10.1371/journal.pone.0005119.s007 (0.26 MB
PDF)
Figure S8 Viability of co-cultures of HMEC-1 cells infected ex
vivo with Ad(I)-F512-TK- and human MIA PaCa-2 cells followed
by GCV. Only the 20:80 ratio (HMEC-1:MIAPaCa-2) is shown.
*P,0.05 (one-way ANOVA followed by a Tukey multiple
comparison test).
Found at: doi:10.1371/journal.pone.0005119.s008 (0.27 MB
PDF)
Figure S9 Effect of conditioned media produced by stromal cells
on CRAd activity. (A) Cellviability after infection of the different cell
types with Ad(I)F512-TK in the presence of different dilutions of
conditioned media obtained from HMEC-1 cells, WI-38 fibroblasts
or their own (B) Similar to A, but the conditioned media was
obtained from pre-infected cells.For further detailssee Figure 7.Cell
viability was assessed at day 6 of infection by using MTT assay.
Found at: doi:10.1371/journal.pone.0005119.s009 (0.37 MB
PDF)
Table S1 Primers sequences. The table shows the sequence of
primers used for the different clonings.
Found at: doi:10.1371/journal.pone.0005119.s010 (0.04 MB
DOC)
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